

## Personal Information

Email: arifakyildiz@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/arifakyildiz>

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Comprehensive analysis of orbital lymphoma in a Turkish cohort: clinical characteristics, histological subtypes, treatment modalities, prognostic factors, and implications for management**  
AKYILDIZ A., Ismayilov R., Rustamova N., Tokatli M., KOÇ İ., AKIN S., KIRATLI H., BARIŞTA İ.  
Annals of Hematology, vol.103, no.3, pp.905-915, 2024 (SCI-Expanded)
- II. **Sirolimus experience in adult patients with vascular malformations**  
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.  
Vascular, 2024 (SCI-Expanded)
- III. **A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology**  
YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.  
Irish Journal of Medical Science, vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded)
- IV. **The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey**  
AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., YILDIZ İ., Iriagac Y., Turhal S., Akbas S., et al.  
Medicine, vol.102, no.45, 2023 (SCI-Expanded)
- V. **A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer**  
YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., YALÇIN Ş.  
Anti-cancer drugs, vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded)
- VI. **Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group**  
Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., YALÇIN Ş., Çoban E., EVRENSEL T., Kalkan Z., et al.  
The oncologist, vol.28, no.10, pp.875-884, 2023 (SCI-Expanded)
- VII. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**  
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.  
Medicine (United States), vol.102, no.18, 2023 (SCI-Expanded)
- VIII. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**  
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.  
Biomarkers in Medicine, vol.17, no.7, pp.379-389, 2023 (SCI-Expanded)
- IX. **Emerging treatment strategies in hepatobiliary cancer**  
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.  
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye**  
Unal C., Selcuk N. A., Biricik F. S., Alan O., Ordu C., Selvi O., Sakin A., Sever N., Topcu Z. A., AKYILDIZ A., et al.  
Eurasian Journal of Medicine and Oncology, vol.7, no.3, pp.232-242, 2023 (ESCI)
- II. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**  
YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.  
Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)
- III. **Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review**  
YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., AKIN S., YALÇIN Ş., BARIŞTA İ.  
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, vol.15, no.4, pp.307-310, 2022 (ESCI)
- IV. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**  
YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.  
Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)

## Metrics

Publication: 13